{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T18:07:00Z","timestamp":1770574020625,"version":"3.49.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>The activity of cabozantinib in nonclear cell histologies has not been evaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>Data were collected across 24 Italian hospitals. Patients were aged 18 years and older with advanced nonclear cell renal cell carcinoma (RCC), with an Eastern Cooperative Oncology Group Performance Status 0 to 2, who had relapsed after previous systemic treatments for metastatic disease. Cabozantinib was administered orally at 60\u2009mg once a day in 28 days cycles. Dose reductions to 40 or 20\u2009mg were made due to toxicity. Adverse events (AEs) were monitored using CTCAE version 4.0.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Seventeen patients were enrolled. Three (18%) patients were diagnosed type I papillary RCC, 9 (53%) type II papillary, 3 (18%) chromophobe, and 2 (11%) with Bellini duct carcinoma. In total, 11 patients started with 60\u2009mg. Six patients started a lower dose of 40\u2009mg. Median progression-free survival was 7.83 months (0.4 to 13.4\u2009mo), while median overall survival was not reached but 1-year overall survival was about 60%. Six patients (35%) experienced a partial response to treatment and 6 patients (35%) showed a stable disease. In the remaining 5 (30%), we observed a progressive disease. Grade 3 and 4 AEs were observed in 41% of patients. Among 20 patients, only 1 (6%) discontinued treatment due to AEs. Asthenia (41%), diarrhea (35%), aminotransferase increasing (35%), mucosal inflammation (35%), hand and foot syndrome (24%), and hypothyroidism (24%) were the most frequently AEs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Our data showed that, cabozantinib is a active and feasible treatment in patient with nonclear cell RCC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000478","type":"journal-article","created":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T21:27:08Z","timestamp":1537997228000},"page":"42-45","source":"Crossref","is-referenced-by-count":18,"title":["Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma"],"prefix":"10.1097","volume":"42","author":[{"given":"Michele","family":"Prisciandaro","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Genitourinary Cancer Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Ratta","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Genitourinary Cancer Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[{"name":"Division of Oncology, S.Orsola-Malpighi Hospital, Bologna"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Fornarini","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, IRCCS Azienda Ospedaliera Universitaria San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genova"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Caponnetto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology B, Policlinico Umberto I \u201cSapienza\u201d University of Rome, Rome"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Iacovelli","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Azienda Ospedaliera Universitaria Integrata (AOUI), University of Verona, Verona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Facchini","sequence":"additional","affiliation":[{"name":"Department of Uro-Gynaecological Oncology, Division of Medical Oncology, Istituto Nazionale Tumori Fondazione G. Pascale (IRCCS)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Scagliarini","sequence":"additional","affiliation":[{"name":"Oncology Unit, Antonio Cardarelli Hospital, Naples"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Sabbatini","sequence":"additional","affiliation":[{"name":"Department of Oncology and Haematology and Respiratory Disease, University Hospital, Modena"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Caserta","sequence":"additional","affiliation":[{"name":"Oncology Department, Santa Maria Hospital, Terni, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Peverelli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Genitourinary Cancer Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Mennitto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Genitourinary Cancer Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Verzoni","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Genitourinary Cancer Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Genitourinary Cancer Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0140-6736(15)00046-X","article-title":"Renal cancer","volume":"387","author":"Capitanio","year":"2016","journal-title":"The Lancet"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO Classification of Tumours of the Urinary System and male genital organs-part A: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.3747\/co.20.1230","article-title":"Management of renal collecting duct carcinoma: a systematic review and the McMaster experience","volume":"20","author":"Dason","year":"2013","journal-title":"Curr Oncol"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/PPO.0b013e31829e3c9a","article-title":"Targeting the hepatocyte growth factor\/c-Met signaling pathway in renal cell carcinoma","volume":"19","author":"Harshman","year":"2013","journal-title":"Cancer J"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"13373","DOI":"10.1073\/pnas.1404848111","article-title":"Direct regulation of GAS6\/AXL signaling by HIF promotes renal metastasis through SRC and MET","volume":"111","author":"Rankin","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"16484","DOI":"10.1073\/pnas.0806574105","article-title":"Kinase requirements in human cells: III. Altered kinase requirements in VHL\u2212\/\u2212 cancer cells detected in a pilot synthetic lethal screen","volume":"105","author":"Bommi-Reddy","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/annonc\/mds463","article-title":"c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma","volume":"24","author":"Gibney","year":"2013","journal-title":"Ann Oncol"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"5902","DOI":"10.1128\/MCB.19.9.5902","article-title":"The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor\/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells","volume":"19","author":"Koochekpour","year":"1999","journal-title":"Mol Cell Biol"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/23808993.2017.1289066","article-title":"Personalized therapy in renal cell carcinoma: are the different tyrosine kinase inhibitors the same for any patient?","volume":"2","author":"Ratta","year":"2017","journal-title":"Expert Rev Prec Med Drug Dev"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1002\/cncr.28151","article-title":"Metastatic non clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium (IMDC) Criteria","volume":"119","author":"Kroeger","year":"2013","journal-title":"Cancer"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.humpath.2005.01.011","article-title":"C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas","volume":"36","author":"Huo","year":"2005","journal-title":"Hum Pathol"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0002-9440(10)65147-4","article-title":"Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype","volume":"155","author":"Lubensky","year":"1999","journal-title":"Am J Pathol"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1093\/annonc\/mdt152","article-title":"Targeted therapies and the treatment of non-clear cell renal cell carcinoma","volume":"24","author":"Bellmunt","year":"2013","journal-title":"Ann Oncol"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.2147\/DDDT.S104225","article-title":"Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy","volume":"10","author":"Grassi","year":"2016","journal-title":"Drug Des Dev Ther"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R21-20230903","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor\u2013targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2012.43.3383","article-title":"Phase II and biomarker study of the dual MET\/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma","volume":"31","author":"Choueiri","year":"2013","journal-title":"J Clin Oncol"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.clgc.2018.03.014","article-title":"Safety and efficacy of cabozantinib in metastatic renal cell carcinoma: real world data from an Italian Managed Access Program (MAP)","volume":"16","author":"Procopio","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.2147\/OTT.S145295","article-title":"Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma","volume":"10","author":"Gerendash","year":"2017","journal-title":"Onco Targets Ther"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000421-201901000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T03:07:27Z","timestamp":1693710447000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201901000-00008"}},"subtitle":["Real-world Data From an Italian Managed Access Program"],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000478","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}